Washington (AP) – The polarizing boss of vaccines at Food and Drug Administration leaves the agency after a brief term that pulled the anger of Biotech company, patient groups and conservative allies of President Donald Trump.
Dr. Vinay Prasad “did not want to be a distraction” and resigned from his role as a top vaccine regulatory authority of the FDA to (*3*), said a spokesman for the Ministry of Health and Human Services in a statement on Tuesday.
Two people familiar with the situation told the Associated Press that Prasad was suppressed after several recent controversy. The people spoke under the condition of anonymity to discuss internal personnel matters.
In May after years as an academic researcher at the University of California San Francisco, Prasad entered the FDA, where he often criticized the FDA’s approach to drug permits and covid 19 vaccines.
His contrary approach seemed to correspond to the FDA commissioner Marty Makary, who repeatedly praised Prasad’s work and intellect.
In the past few weeks, however, Prasad has become the goal of conservative activists, including Laura Loomer, who criticized the former statements of Prasad, who criticized Trump, and praised Liberal -independent Senator Bernie Sanders.
“How did this Trump-Hass-Bernie Bro get into the Trump administrator?” Loomer posted on X last week.
Prasad was also checked for his treatment of a recently approved security problem for the only approved gene therapy for Duchenne’s muscular dystrophy.
Under his leadership, the deliveries of the therapy were briefly stopped after a number of deaths of patients and resumed in the slow Monday after singing of families of boys with the fatal muscle loss disease.
Prasad has long been skeptical about therapy and other medicines of muscular dystrophy sold by drug maker Sarepta Therapeutics. As an academic, Prasad gained adjacent by attacking the FDA because he was too forgiving in his standards for the escalate in cancer medication and other up-to-date therapies.
This approach contradicts Trump’s republican supporters who generally prefer faster approvals and unrestricted access to experimental treatments. During Trump’s first term, he signed the law of “right to attempt”, a largely symbolic law that received the support of conservatives in the population, the dying patients enabled extended access to unproven medication.
Prasad’s decision to pause Sarepta’s therapy was criticized last week by a columnist and the editorial board of Wall Street Journal.
Regardless of this, the Prasad department gave rejection letters to three miniature biotech companies this month, which aimed to approved for up-to-date gene therapies.
Prasad’s predecessor in the role, Dr. Peter Marks, supervised a powerful escalate in approvals for up-to-date gene therapies that aim to treat or prevent diseases by replacing or changing part of the genetic code of the patient.
Prasad was a pronounced critic of the guidance of Marks at the FDA. This included monitoring the approval of the first Covid vaccines and therapies.
___
The Department of Health and Science Department of Associated Press receives support from the Department of Science Education of the Howard Hughes Medical Institute and Robert Wood Johnson Foundation. The AP is only responsible for all content.
